| Name | Title | Contact Details |
|---|
Balance Pharmaceuticals is a Pacific Palisades, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Horton and Converse Pharmacies is a Newport Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Greenstone is a Peapack, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
TwelveStone is focused on the medication needs of patients with complex and chronic conditions. For more than 35 years, TwelveStone has been dedicated to finding new ways to deliver care designed around the patient. Chronic conditions include Multiple Sclerosis, Cystic Fibrosis, Hemophilia, Crohn`s Disease, Growth Deficiency, HIV, Leukemia, and many others. For patients, we provide access to the most advanced medications, along with the personal and financial support patients need to live with chronic conditions. For providers, we simplify treatment for complex conditions by eliminating the administrative and clinical burdens placed on your practice when patients need innovative specialty medication. Providers we serve: • Hospitals • Long-Term Care • Hospice • Home Care • Specialty Clinics Solutions include: • MEDIpack-Medication made simple, efficient, and accurate • Infusion & Enteral Services- Home infusion, infusion services, and infusion centers • Respiratory Equipment -In partnership with AeroCare From comprehensive medication support to peer advocates and a team of pharmacy support professionals, TwelveStone Health Partners supports the transition from acute to post-acute care environments and the journey from sickness to health. We are currently licensed in 30 states: Alaska, Arizona, Colorado, Florida, Georgia, Illinois, Iowa, Kentucky, Louisiana, Maine, Minnesota, Mississippi, Missouri, Montana, Nevada, New Hampshire, New Jersey, North Carolina, North Dakota, New York, Ohio, Oklahoma, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Washington, Wisconsin and Wyoming.
Trefoil is a biotechnology company focused on leveraging its engineered fibroblast growth factor-1 protein (eFGF-1) technology platform to develop first-in-class regenerative pharmacologic treatments for corneal diseases, which are debilitating and cause a significant amount of preventable blindness throughout the world.